JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.27 -2.97

Resumen

Variación precio

24h

Actual

Mínimo

3.21

Máximo

3.49

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+26.11% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

159M

1.2B

Apertura anterior

6.24

Cierre anterior

3.27

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 feb 2026, 23:11 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Ganancias

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Adquisiciones, fusiones, absorciones

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Adquisiciones, fusiones, absorciones

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Adquisiciones, fusiones, absorciones

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Charlas de Mercado

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Ganancias

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Ganancias

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Ganancias

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Ganancias

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Ganancias

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Ganancias

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Ganancias

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Charlas de Mercado

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Ganancias

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Ganancias

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Ganancias

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

26.11% repunte

Estimación a 12 meses

Media 4.25 USD  26.11%

Máximo 4.5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat